Tenax Therapeutics, Inc. (NASDAQ:TENX) Sees Large Decline in Short Interest

Tenax Therapeutics, Inc. (NASDAQ:TENX) saw a large drop in short interest in July. As of July 31st, there was short interest totalling 10,400 shares, a drop of 56.7% from the July 15th total of 24,000 shares. Currently, 0.6% of the company’s stock are short sold. Based on an average trading volume of 481,600 shares, the days-to-cover ratio is presently 0.0 days.

Tenax Therapeutics Price Performance

NASDAQ TENX traded up $0.42 during trading hours on Tuesday, hitting $4.03. The company’s stock had a trading volume of 157,131 shares, compared to its average volume of 351,791. The company’s 50 day simple moving average is $3.33 and its two-hundred day simple moving average is $4.12. Tenax Therapeutics has a 12 month low of $2.77 and a 12 month high of $61.20.

Tenax Therapeutics (NASDAQ:TENX) last posted its quarterly earnings data on Tuesday, May 14th. The specialty pharmaceutical company reported ($3.12) EPS for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.72). On average, sell-side analysts forecast that Tenax Therapeutics will post -7.96 EPS for the current year.

Wall Street Analyst Weigh In

Separately, StockNews.com assumed coverage on Tenax Therapeutics in a research note on Friday. They issued a “sell” rating on the stock.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.